<DOC>
	<DOC>NCT00401076</DOC>
	<brief_summary>This study is to evaluate the safety of 3.0 g/day of SA-001 (to be flexibly increased or decreased with the range from 1.5 g/day to 6.0 g/day), which will orally be administered for 52 weeks to patients with pancreatic exocrine insufficiency caused by chronic pancreatitis in the non-compensatory stage or by pancreatectomy.</brief_summary>
	<brief_title>A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pancreatitis, Chronic</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Inclusion Criteria Subjects who complete the S245.3.122 clinical study (excluding discontinued subjects). Exclusion Criteria Subjects who are assessed to be inappropriate for continuing longterm use of SA001, at the discretion of the investigator or the subinvestigator, because they experienced adverse drug reactions in the S245.3.122 clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>SA-001</keyword>
	<keyword>Pancreatic Exocrine Insufficiency</keyword>
	<keyword>Chronic Pancreatitis</keyword>
	<keyword>Pancreatectomy</keyword>
</DOC>